Merck & Co., Inc.
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30250% above fair value
$149.52+3.19 (+2.18%)
Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%
Merck Organon by Quarter
Organon — Marvelon / Mercilon (oral contraceptives) U.S. sales ($M) ($M)
Merck Organon: $0M in Q2 2026. That is the highest of the 18 quarters on record here.
Latest, Q2 2026
0
Period ended Jun 30, 2026
Change on a year earlier
–
0 in Q2 2025
History
18 quarters
Since Q1 2022
Sources
13
Documents cited below
Where the Q2 2026 figure comes from
Source: Organon & Co. SEC Filing (0001628280-26-051230) ↗
Reported in Organon & Co. Form 10-Q / 10-K (CIK 0001821825).
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). Merck Organon ($M), quarterly Q1 2022–Q2 2026 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/ogn-marvelonmercilon-us
See every metric in the Merck KPI table. Data updated Oct 26, 2026.